Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9693375 | 0.81 | KDM4E (0.31) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL27574664 | 0.76 | KDM4E (0.31) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL30726103 | 0.75 | CALM1 (0.33) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL567392 | 0.75 | ALDH1A1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL6423807 | 0.75 | ALDH1A1 (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL27691106 | 0.74 | KEAP1 (0.30) | — | |
| SCHEMBL6850250 | 0.74 | — | — | |
| SCHEMBL27791467 | 0.72 | — | — | |
| SCHEMBL29104904 | 0.71 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD | |
| SCHEMBL28986086 | 0.71 | KDM4E (0.33) | KDM4EMEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | claimed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| EP-1027350-A1 | AMINOMETHYL-BENZO A]QUINOLIZIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATIONS FOR NEURODEGENRATIVE DISEASES | PIERRE FABRE MEDICAMENT (FR) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999021856-A1 | AMINOMETHYL-BENZO[A]QUINOLIZIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATIONS FOR NEURODEGENRATIVE DISEASES | PIERRE FABRE MEDICAMENT (FR) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | KDM4E 3469/4885MEN1 4850/4885ALDH1A1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.